{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:47:34Z","timestamp":1790286454136,"version":"4.1.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1097\/md.0000000000002534","type":"journal-article","created":{"date-parts":[[2016,1,28]],"date-time":"2016-01-28T09:07:22Z","timestamp":1453972042000},"page":"e2534","source":"Crossref","is-referenced-by-count":32,"title":["Rifaximin for Irritable Bowel Syndrome"],"prefix":"10.1097","volume":"95","author":[{"given":"Jun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20210226","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"R2-19-20210226","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1440-1746.2006.04672.x","article-title":"Irritable bowel syndrome in the 21st century: perspectives from Asia or South-east Asia","volume":"22","author":"Chang","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"R3-19-20210226","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1440-1746.2009.06120.x","article-title":"Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners","volume":"25","author":"Grundmann","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"R4-19-20210226","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3109\/00365521.2013.775328","article-title":"The epidemiology of irritable bowel syndrome in Denmark: a population-based survey in adults \u2264 50 years of age","volume":"48","author":"Krogsgaard","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"R5-19-20210226","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.3748\/wjg.v20.i10.2456","article-title":"Irritable bowel syndrome: emerging paradigm in pathophysiology","volume":"20","author":"Lee","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R6-19-20210226","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1079\/BJN2002631","article-title":"A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics","volume":"88","author":"Madden","year":"2002","journal-title":"Br J Nutr"},{"key":"R7-19-20210226","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00042737-200103000-00001","article-title":"Irritable bowel syndrome: is the search for lactose intolerance justified?","volume":"13","author":"Parker","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R8-19-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2036.2004.02036.x","article-title":"New pathophysiological mechanisms in irritable bowel syndrome","volume":"20","author":"Barbara","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-19-20210226","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/gut.2006.108712","article-title":"Small intestinal bacterial overgrowth in patients with irritable bowel syndrome","volume":"56","author":"Posserud","year":"2007","journal-title":"Gut"},{"key":"R10-19-20210226","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s10620-012-2033-7","article-title":"The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome","volume":"57","author":"Pyleris","year":"2012","journal-title":"Dig Dis Sci"},{"key":"R11-19-20210226","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1053\/j.gastro.2009.02.074","article-title":"Postinfectious irritable bowel syndrome","volume":"136","author":"Spiller","year":"2009","journal-title":"Gastroenterology"},{"key":"R12-19-20210226","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.3748\/wjg.v16.i24.2978","article-title":"Small intestinal bacterial overgrowth syndrome","volume":"16","author":"Bures","year":"2010","journal-title":"World J Gastroenterol"},{"key":"R13-19-20210226","first-page":"139","article-title":"Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial","volume":"52","author":"Majewski","year":"2007","journal-title":"Adv Med Sci"},{"key":"R14-19-20210226","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2982.2010.01637.x","article-title":"PhyloChip microarray analysis reveals altered gastrointestinal microbial communities in a rat model of colonic hypersensitivity","volume":"23","author":"Nelson","year":"2011","journal-title":"Neurogastroenterol Motil"},{"key":"R15-19-20210226","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1757-4749-2-19","article-title":"Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome","volume":"2","author":"Carroll","year":"2010","journal-title":"Gut Pathog"},{"key":"R16-19-20210226","doi-asserted-by":"crossref","first-page":"14407","DOI":"10.3748\/wjg.v20.i39.14407","article-title":"Bloating and functional gastro-intestinal disorders: where are we and where are we going?","volume":"20","author":"Iovino","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R17-19-20210226","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1572-0241.2007.01072.x","article-title":"The degree of breath methane production in IBS correlates with the severity of constipation","volume":"102","author":"Chatterjee","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R18-19-20210226","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1136\/gutjnl-2011-301213","article-title":"Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFalpha","volume":"62","author":"Swan","year":"2013","journal-title":"Gut"},{"key":"R19-19-20210226","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1210\/endo.139.9.6202","article-title":"Peptide YY, glucagon-like peptide-1, and neurotensin responses to luminal factors in the isolated vascularly perfused rat ileum","volume":"139","author":"Dumoulin","year":"1998","journal-title":"Endocrinology"},{"key":"R20-19-20210226","doi-asserted-by":"crossref","first-page":"258","DOI":"10.5056\/jnm.2012.18.3.258","article-title":"An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome","volume":"18","author":"Spiller","year":"2012","journal-title":"J Neurogastroenterol Motil"},{"key":"R21-19-20210226","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/MCG.0b013e3181a099a5","article-title":"Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution","volume":"43","author":"Parodi","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"R22-19-20210226","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1592\/phco.27.10.1361","article-title":"The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers","volume":"27","author":"Pentikis","year":"2007","journal-title":"Pharmacotherapy"},{"key":"R23-19-20210226","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.clinthera.2011.06.007","article-title":"Rifaximin: new therapeutic indication and future directions","volume":"33","author":"Rivkin","year":"2011","journal-title":"Clin Ther"},{"key":"R24-19-20210226","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N Engl J Med"},{"key":"R25-19-20210226","doi-asserted-by":"crossref","first-page":"A","DOI":"10.1016\/S0016-5085(08)62544-5","article-title":"T1390 rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response","volume":"134","author":"Lembo","year":"2008","journal-title":"Gastroenterology"},{"key":"R26-19-20210226","doi-asserted-by":"crossref","first-page":"557","DOI":"10.7326\/0003-4819-145-8-200610170-00004","article-title":"The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial","volume":"145","author":"Pimentel","year":"2006","journal-title":"Ann Intern Med"},{"key":"R27-19-20210226","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2006.00458.x","article-title":"A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence","volume":"101","author":"Sharara","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R29-19-20210226","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"R30-19-20210226","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1592\/phco.28.8.1019","article-title":"Rifaximin for the treatment of hepatic encephalopathy","volume":"28","author":"Lawrence","year":"2008","journal-title":"Pharmacotherapy"},{"key":"R31-19-20210226","first-page":"19","article-title":"Rifaximin: a nonabsorbed oral antibiotic","volume":"5","author":"Baker","year":"2005","journal-title":"Rev Gastroenterol Disord"},{"key":"R32-19-20210226","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/j.1365-2036.2010.04296.x","article-title":"Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers\u2019 diarrhoea","volume":"31","author":"Layer","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"R33-19-20210226","first-page":"1314","article-title":"Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome","volume":"17","author":"Scarpellini","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R34-19-20210226","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/apt.12087","article-title":"Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months","volume":"36","author":"Meyrat","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R35-19-20210226","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000362405","article-title":"Medication management of irritable bowel syndrome","volume":"89","author":"Trinkley","year":"2014","journal-title":"Digestion"},{"key":"R36-19-20210226","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJMe1011211","article-title":"Antibiotic therapy for the irritable bowel syndrome","volume":"364","author":"Tack","year":"2011","journal-title":"N Engl J Med"},{"key":"R37-19-20210226","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/j.1572-0241.2008.02030.x","article-title":"Small intestinal bacterial overgrowth recurrence after antibiotic therapy","volume":"103","author":"Lauritano","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R38-19-20210226","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/MCG.0b013e31825828a7","article-title":"Pre-cebo\u201d: an unrecognized issue in the interpretation of adequate relief during irritable bowel syndrome drug trials","volume":"46","author":"Kim","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"R39-19-20210226","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12664-013-0365-7","article-title":"Comparison of Manning, Rome I, II, and III, and Asian diagnostic criteria: report of the Multicentric Indian Irritable Bowel Syndrome (MIIBS) study","volume":"32","author":"Ghoshal","year":"2013","journal-title":"Indian J Gastroenterol"},{"key":"R40-19-20210226","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1001\/archinte.161.17.2081","article-title":"Evidence- and consensus-based practice guidelines for the diagnosis of irritable bowel syndrome","volume":"161","author":"Fass","year":"2001","journal-title":"Arch Intern Med"},{"key":"R41-19-20210226","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1111\/j.1572-0241.2002.07026.x","article-title":"Utility of the Rome I and Rome II criteria for irritable bowel syndrome in U.S. women","volume":"97","author":"Chey","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R42-19-20210226","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1440-1746.2011.06930.x","article-title":"Subtypes of irritable bowel syndrome on Rome III criteria: a multicenter study","volume":"27","author":"Yao","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"R43-19-20210226","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/MCG.0b013e31815bd749","article-title":"Irritable bowel syndrome subtypes defined by Rome II and Rome III criteria are similar","volume":"43","author":"Dorn","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"R44-19-20210226","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1007\/s10620-014-3157-8","article-title":"Antibiotic treatment of constipation-predominant irritable bowel syndrome","volume":"59","author":"Pimentel","year":"2014","journal-title":"Dig Dis Sci"},{"key":"R45-19-20210226","first-page":"85","article-title":"Role of gut microflora and probiotic effects in the irritable bowel syndrome","volume":"77","author":"Fanigliulo","year":"2006","journal-title":"Acta Biomed"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000002534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:58:35Z","timestamp":1620961115000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201601250-00019"}},"subtitle":["A Meta-Analysis of Randomized Placebo-Controlled Trials"],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000002534","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}